RxDoctor Payments Data

Arathi Komarla, MD

Gastroenterology · Manchester, NHNPI 1619935111

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $712 of the $808 with a category attached, or 88.1%. It is spread thinly across 9 manufacturers, the largest accounting for just 20.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $227 and has fallen 80.7% since, to $44 in 2025.

$808in general payments, 2019–2025

Across 18 payments — averaging $44.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$164
  • AbbVie$153
  • Regeneron Healthcare Solutions, Inc.$115
  • Lilly USA, LLC$107
  • Janssen Scientific Affairs, LLC$103
  • Gilead$77
  • plus $89 from 3 others

What the payments were for

  • Food & beverage$71288%
  • Education$9612%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$808 in reported general payments places this provider in the 55th percentile of 91 gastroenterology providers in New Hampshire.

See all gastroenterology providers in New Hampshire

Medicare billing

Part B allowed, 2024
$48,917
Medicare patients
184
Services billed
379

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide14$14,612
Sucralfate14$4,078
Omeprazole84$978
Pantoprazole Sodium33$728
Famotidine66$588
Dexlansoprazole DrDexlansoprazole19$3

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$153$14,61214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 91 gastroenterology providers in New Hampshire.

Other gastroenterology in Manchester

See the full list for New Hampshire

Where these figures come from

Is this you, or does something look wrong? →